Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates

Citius Oncology (NASDAQ:CTOR) announced its quarterly earnings results on Friday. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06), FiscalAI reports. The firm had revenue of $3.94 million for the quarter, compared to analysts’ expectations of $4.37 million.

Citius Oncology Trading Up 2.6%

NASDAQ CTOR traded up $0.03 during mid-day trading on Friday, hitting $1.21. The company’s stock had a trading volume of 145,894 shares, compared to its average volume of 223,311. The stock’s fifty day simple moving average is $1.12 and its two-hundred day simple moving average is $1.51. The firm has a market capitalization of $106.91 million, a P/E ratio of -3.57 and a beta of 3.09. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.56 and a quick ratio of 0.11. Citius Oncology has a 52-week low of $0.55 and a 52-week high of $6.19.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Oncology in a research note on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Citius Oncology presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Institutional Trading of Citius Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in CTOR. Citadel Advisors LLC acquired a new position in shares of Citius Oncology in the 3rd quarter valued at about $36,000. Bank of America Corp DE increased its position in Citius Oncology by 5,256.9% during the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after buying an additional 8,411 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Citius Oncology by 31.6% during the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock worth $220,000 after purchasing an additional 52,875 shares during the last quarter. Jane Street Group LLC acquired a new stake in Citius Oncology during the second quarter worth about $465,000. Finally, Armistice Capital LLC bought a new stake in Citius Oncology in the third quarter valued at about $15,582,000. Institutional investors own 70.52% of the company’s stock.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.